Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

David Hilbert

Arcellx, Inc.

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Li Lab of Computational Cancer Immunology focuses on cancer research, particularly on the computational analysis of immune responses in cancer. The lab has conducted various studies related to T cell receptor repertoires, mitochondrial transfer between cells, and cancer immunotherapy.

Li Lab of Computational Cancer Immunology

We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies.


Kite Pharma

JVC Investment Partners

LG Technology Ventures

Solasta Ventures

Samsara BioCapital

Novo Holdings

Adage Capital Management

Asymmetry Ventures

CaaS Capital Management

Cambrian Biopharma

CAM Capital

Clough Capital Partners

Soleus Capital

SR One

Surveyor Capital

Suvretta Capital Management

Takeda Ventures

Terra Magnum Capital Partners (""""TMCP"""")""

Arcellx

Metric
Company Name	Arcellx, Inc.	Therini Bio	Li Lab of Computational Cancer Immunology
Symbol	ACLX
MSH ID	COM:ARCELLX	COM:THERINIBIO	ORG:LILAB-UTSW
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US
Stage
Employee Count	130
Website	arcellx.com	therinibio.com	lilab-utsw.org
LinkedIn	arcellx	therinibio
Founders

Metric
Market Cap	3.07B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	110.32M
Revenue (LTM)
Revenue (NTM)
Gross Profit	108.28M
EBITDA	-87.84M
Operating Income	-89.88M
Net Income	-70.69M
EPS	-1.47
Diluted EPS	-1.47
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.98
Operating Profit Margin	-0.56
EBITDA Margin	-0.80
Net Profit Margin	-0.37
Return on Equity	-0.12
Return on Assets	-0.06
Return on Capital Employed	-0.11

COM:ARCELLX

Arcellx, Inc.

Last Close

87.22

22/11 21:00

Market Cap

3.07B

Beta: -

Volume Today

342.91K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-24.88
P/B Ratio	12.08
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	35.97
EV Multiple	-38.62

Metric
Days Sales Outstanding	298.70
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	8.59
Cash Conversion Cycle	-366.40
Asset Turnover	0.20

Metric
Operating Cash Flow	207.57M
Free Cash Flow	186.15M
Cash Flow to Debt	2.13
Operating Cash Flow/Sales	1.88
Free Cash Flow Yield	0.03

Metric
Cash & Equivalents	394.58M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization	0.17
Debt to Assets	0.18
Current Ratio	2.84
Quick Ratio	6.01

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.78
R&D to Revenue	2.78
SG&A to Revenue	1.29